Clinical trials
Carcinoma clinical trials
Below are recruiting carcinoma clinical trials, each written for real people, not researchers. We’re tracking 3,117 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06875310RecruitingPhase 3
Study of adagrasib plus pembrolizumab plus chemotherapy for KRAS G12C lung cancer
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
Birmingham, AlabamaAges 18 years+ - NCT06862219RecruitingPhase 4
Enfortumab Vedotin safety study for advanced urothelial cancer
This study tests a new drug called enfortumab vedotin for people whose advanced urothelial cancer (bladder or urinary tract cancer) has not responded to prior immunotherapy (checkpoint inhibitors) and platinum chemotherapy. The goal is to see how safe and effective this treatment is for Indian adults.
Patna, BiharAges 18 years+ - NCT06868277RecruitingPhase 3
Comparing two drugs for first-line treatment of advanced lung cancer
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer that has high levels of PD-L1 protein. The goal is to see which drug works better as a first treatment before any other cancer therapy.
La Mesa, CaliforniaAges 18 years+ - NCT06860971RecruitingPhase 3
AL2846 capsule vs placebo for advanced thyroid cancer
This study tests a new oral capsule (AL2846) against a placebo in people with advanced thyroid cancer that no longer responds to radioactive iodine. The goal is to see if AL2846 can slow or stop cancer growth.
Hefei, AnhuiAges 18–75 - NCT06862869Recruiting
Alectinib after surgery for early ALK-positive lung cancer
This study looks at how well alectinib works when given after surgery to people with early-stage ALK-positive non-small cell lung cancer. It aims to understand real-world outcomes for patients who take this targeted therapy as their first treatment after surgery.
Zhanjiang, GuangdongAges 18 years+ - NCT06861452RecruitingPhase 1/Phase 2
Testing a new drug after chemo for advanced pancreatic cancer
This study tests an investigational drug (RR001) given after chemotherapy for people with locally advanced pancreatic cancer that hasn't spread. It aims to see if the new treatment is safe and may help shrink tumors that can be reached with a needle injection.
Modena, ItalyAges 18 years+ - NCT06863831Enrolling by invitation
Comparing YSQTG to placebo with standard treatment for esophageal cancer
This trial tests whether adding an herbal granule (YSQTG) to standard chemotherapy with or without immunotherapy helps patients with a specific type of advanced esophageal cancer. It focuses on people whose cancer is stage III to IVa and who have not had treatment yet.
Beijing, ChaoyangAges 18–80 - NCT06865768RecruitingPhase 2
New PET-MRI scan for better prostate biopsy guidance
This trial tests a new imaging scan that combines a special PET tracer with MRI to help guide a prostate biopsy. The goal is to see if this scan can more accurately find cancer and reduce the need for extra biopsies.
Atlanta, GeorgiaAges 18 years+ - NCT06228079RecruitingPhase 3
Chemo-immunotherapy after surgery for early reoccurring nasopharyngeal cancer
This study looks at whether adding chemo-immunotherapy after surgery is better than surgery alone for patients whose nasopharyngeal cancer has returned but is still in early stages. It may help prevent the cancer from coming back again.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06855771RecruitingPhase 2
Study of navlimetostat alone or with izalontamab for advanced lung cancer
This trial tests a new drug, navlimetostat, either by itself or combined with another drug, izalontamab, for people with advanced non-small cell lung cancer that has a specific genetic change (MTAP loss). The goal is to see if these treatments can help shrink tumors or slow cancer growth.
Anchorage, AlaskaAges 18 years+ - NCT06848868RecruitingPhase 1
Clinic-based scope for bladder cancer follow-up
This trial tests if a procedure done in the clinic, without general anesthesia, can safely check the upper urinary tract after kidney-sparing surgery for urothelial cancer. It may reduce the need for hospital visits.
Hong KongAges 18 years+ - NCT06850103RecruitingPhase 2
Chemo, radiation, and immunotherapy for advanced rectal cancer that has spread a little
This trial tests a combination of chemotherapy, radiation, and an immunotherapy drug (serplulimab) for people with rectal cancer that has spread to just a few spots in the body (no more than 5 tumors in up to 2 locations). It aims to see if this approach is safe and effective.
Hangzhou, ZhejiangAges 18–75 - NCT06792721Recruiting
Measuring mutation levels in siblings with BRCA risk
This study looks at how genetic mutations (changes in DNA) are measured in the blood of sisters. One sister has a BRCA1 or BRCA2 gene mutation that raises cancer risk, and the other does not. The goal is to understand mutation differences between them.
Caen, FranceAges 30–50 - NCT06840886RecruitingPhase 1
Study of PHST001 for advanced solid tumors
This trial tests an experimental drug called PHST001 for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if PHST001 can help shrink or control the tumor.
Beverly Hills, CaliforniaAges 18 years+ - NCT06841172RecruitingPhase 3
Radiation vs treatment switch for limited liver cancer growth
This trial tests whether giving radiation to a few growing cancer spots while continuing your current treatment works better than switching to a new treatment right away. It's for people whose advanced liver cancer has only barely started to progress on their first therapy.
Jinan, ShandongAges 18–75 - NCT06843434RecruitingPhase 2
Study of two immunotherapy drugs for rectal cancer
This trial tests a combination of two immunotherapy drugs, botensilimab and balstilimab, for people with newly diagnosed rectal adenocarcinoma that has not spread. The goal is to see if this treatment can shrink the tumor before surgery.
Basking Ridge, New JerseyAges 18 years+ - NCT06839105RecruitingPhase 1
Testing AWT020 for advanced cancers
This study tests an experimental drug called AWT020 in people with advanced cancers that have either stopped responding to standard treatments or aren't candidates for them. The goal is to see if AWT020 is safe and tolerable across several cancer types such as lung cancer, melanoma, colorectal cancer, kidney cancer, and others.
Fuzhou, FujianAges 18 years+ - NCT06833073RecruitingPhase 2
Study of an mRNA vaccine and BCG for bladder cancer
This trial tests an experimental mRNA vaccine (V940) combined with BCG therapy for people with high-risk non-muscle invasive bladder cancer that hasn't spread. It aims to see if the vaccine can help the immune system better fight the cancer.
Bakersfield, CaliforniaAges 18 years+ - NCT06830694RecruitingPhase 2
Trial of a new drug combo for a rare type of lung cancer
This trial tests a new drug (tarlatamab) combined with chemotherapy and immunotherapy for people whose lung cancer has changed from one type (adenocarcinoma) to small cell lung cancer after treatment with EGFR targeted therapy. The goal is to see if this combination is safe and works well.
Seoul, Gangnam-guAges 19 years+ - NCT06834152Recruiting
Online adaptive radiation for localized prostate cancer
This trial tests a new way to deliver high-precision radiation to the prostate using daily MRI or CT scans to adjust the treatment based on your exact anatomy. It aims to make radiation more accurate and reduce side effects.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT06831149RecruitingPhase 2
Spy imaging to reduce fistulas after throat reconstruction
This study is testing a special imaging tool (SPY system) that helps surgeons see blood flow better during surgery to rebuild the throat. The goal is to reduce the risk of fluid leaks (fistulas) after the operation.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06833255Recruiting
Support Program for Black Women Breast Cancer Survivors
This program pairs Black women who have completed breast cancer treatment with support to help them transition into survivorship. It offers mentorship based on how recently you finished treatment, with priority for those who had limited support or who identify as African American.
Buffalo, New YorkAges 18 years+ - NCT06819228RecruitingPhase 1
Lighted antibody imaging in head and neck cancer surgery
This trial tests a special fluorescent dye attached to panitumumab, a cancer-targeting antibody, to help surgeons see tumor tissue more clearly during head and neck cancer surgery. The goal is to improve removal of all cancer cells while sparing healthy tissue.
Nashville, TennesseeAges 18 years+ - NCT06817161RecruitingPhase 3
Nerve stimulation for quality of life during ovarian cancer treatment
This trial tests if a gentle nerve stimulation device on the ear can improve quality of life for people with ovarian cancer who are starting their first chemotherapy. It may help manage symptoms like fatigue or feeling sick.
CaenAges 18 years+
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carcinoma?
- Yes. Clin2 currently lists 3,117 recruiting carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.